Cardiovascular events during differing hypertension therapies in patients with diabetes. - Wikidata - wikimedia - TriplyDB

Cardiovascular events during differing hypertension therapies in patients with diabetes.

Cardiovascular events during differing hypertension therapies in patients with diabetes.

http://www.wikidata.org/entity/Q39858492

about

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Evidence-based hypertension treatment in patients with diabetes The perils of surrogate endpoints Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SB Hypertension management 2011: optimal combination therapy.Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.Blood pressure lowering in patients with diabetes--one level might not fit all.Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis.Hypertension in people with type 2 diabetes: Update on pharmacologic management.Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide Electrolyte disturbance with diuretics and ACEIs Blood pressure control in type 2 diabetic patients.Type 2 diabetes mellitus and hypertension: an update.Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial.Antihypertensive and organ-protective effects of benazepril.Optimal therapy in hypertensive subjects with diabetes mellitus.Hypertension in 2010: Blood pressure and the kidney.Hypertension complicating diabetic pregnancies: pathophysiology, management, and controversies.What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients.Diabetes mellitus and the heart.Treatment of hypertension in diabetes: what is the best therapeutic option?Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension.Role of dihydropyridinic calcium channel blockers in the management of hypertension.What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and Cons.Benefits of delapril in hypertensive patients along the cardiovascular continuum.Role of ambulatory blood pressure monitoring in hypertension and diabetes.Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.Update on blood pressure goals in diabetes mellitus.Is cardiovascular risk reduction therapy effective in South Asian, Chinese and other patients with diabetes? A population-based cohort study from Canada.Hypertension and stroke: an appraisal of the evidence and implications for clinical management.Treatment of hypertensive patients with diabetes: beyond blood pressure control and focus on manidipine.Clinical roles of calcium channel blockers in ischemic heart diseases.Hypertension: Cardiovascular benefits of lowering blood pressure.Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial.Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.Manidipine: an antihypertensive drug with positive effects on metabolic parameters and adrenergic tone in patients with diabetes.The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study.

P2860

Q22241786-21F82BEA-C99E-45A4-B209-954C7BD93C23 Q26851738-1FB2C03E-B582-4F70-8635-C7759484C85A Q27025740-F7E14393-A5E2-4C24-A1C4-2472C7102911 Q33690702-5950CCD2-1BE0-4735-8EA0-1367AD23C9F8 Q33908782-70113500-0BBE-4247-889E-8613626275FE Q34194758-457CBCE9-3E15-441B-A6FA-175406FF60EB Q34380070-CA0B0012-E3DA-43CA-9042-2CE24F765008 Q34467152-31CFD648-3345-44DC-8A3A-FE98CB2F0D8C Q34555388-74D9C685-A1F7-4EFD-AD63-35BF33491069 Q35213902-7165AE94-92FB-4B39-93F4-FE3AC23EABDB Q35416556-080EC6DB-039C-4683-8B8A-25DA5598CC58 Q37113008-E70EBAC9-FDC1-43CD-93D9-765A6917DCF3 Q37566950-D86B4911-2E59-48F4-9D01-1C0D7EAA1EC9 Q37617567-26A33AF9-28F6-485E-B441-1EFA21D33064 Q37634845-306219DC-94F9-4F5A-8244-86A76C102813 Q37812376-3453ED1F-4F09-44A9-ACAC-DD61F7381FF7 Q37828455-13C454C5-F2A5-448B-AB46-F554102309A6 Q37833490-04FC5801-0547-4DCD-A56D-720709000A80 Q37861890-04EEF785-28C6-49C8-9ECC-75751BF54B36 Q37910062-C7B1DAE8-16BC-448F-95E5-3FDA58A119EA Q37936466-58CC1B69-DA06-4508-B582-6DDD546A35D3 Q38018724-74C2CBCF-6584-41FA-9A87-9B7DA026B1F4 Q38034806-EE99E534-4C77-44ED-A4B8-8CBEBCE1123E Q38063564-970DBBD0-78D6-4CC2-A1A2-A27500D03308 Q38069195-3D2FDD37-9C55-40EF-A622-645FF17063EF Q38071013-EEF6A3CA-D0A7-4304-B414-24FB4280C18E Q38087379-15E3ECA8-0CB4-4BF6-AEC2-A99B15C58B0A Q38099768-BA8B695E-29C6-4736-87FF-539F035E9A82 Q38169038-2EAC4A81-29DF-4412-B87B-B12D28003359 Q38433796-64FA22E6-7BE9-4A26-A419-DD55F713CF6D Q38634765-B55E48C8-815B-420A-BDDF-12D13325EF37 Q38702269-E439FE87-D004-4BF3-A4A6-E4D4C66BCF13 Q38862881-4853DD3C-0627-4B70-B07F-81C030658A1D Q39103506-73C4F77D-305A-4F36-B29D-03D5176DF3A0 Q40882948-5768D118-BDEC-4E7D-8C29-A1A01CBC85F1 Q42703643-75F6BB5B-8A5C-48BB-BE8F-D35A3B368036 Q49205064-6DEDF2CD-ED14-49F3-A417-A3EFECE8F13A Q49418865-0108F579-3343-4DDF-B7C0-007389C3154E Q51355247-A4D59AC0-BB3C-49E7-8FA9-7A2AD391A789 Q52639492-00D9DD8D-F014-4786-8E64-7DD7B7256BEB

P2860

Cardiovascular events during differing hypertension therapies in patients with diabetes.

http://www.wikidata.org/entity/Q39858492

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Cardiovascular events during differing hypertension therapies in patients with diabetes.

@en

Cardiovascular events during differing hypertension therapies in patients with diabetes.

@nl

type

label

Cardiovascular events during differing hypertension therapies in patients with diabetes.

@en

Cardiovascular events during differing hypertension therapies in patients with diabetes.

@nl

prefLabel

Cardiovascular events during differing hypertension therapies in patients with diabetes.

@en

Cardiovascular events during differing hypertension therapies in patients with diabetes.

@nl

P1433

Q39858492-6E5A46C3-32F1-4F4D-84B8-AAC93FEEC029

P1476

Q39858492-ABE4D67D-3289-473D-A48A-4A2E56B4EC76

P2093

Q39858492-03CC6F45-01CE-45B7-B399-6A79BF0EB6A3

Q39858492-1CFC3670-939D-4859-BD10-B651AEA11549

Q39858492-4E86728D-C168-48FF-AF35-C62CB5A006E8

Q39858492-77606D08-7B42-43C2-9232-15DFAD180749

Q39858492-861C1755-E5DB-4924-909E-BE3FAF1C564C

Q39858492-8BA482CB-C989-4E0F-A355-2C87B16A46EA

Q39858492-CB14B7F1-39C4-4715-A41E-1BFD9EF59BA4

Q39858492-E8B2B8D6-CF01-4550-9113-F500BBD6E3E7

Q39858492-EC5D9BD0-29DB-49FB-82A9-1B42D752A769

P304

Q39858492-94C9ED14-39F1-4324-98E3-7A40AC49F2F3

P31

Q39858492-3995E8AD-F5F9-497E-9745-CEE9FE8A3F71

P356

Q39858492-55836C55-5FDB-4F08-8EC6-262FB2B8F59D

P407

Q39858492-762551D6-7518-427E-9A26-58FA416CC120

P433

Q39858492-0AF027F3-9F04-4260-990E-4BBE415DDD74

P478

Q39858492-109CE9D6-8105-42BA-A485-A1B19BCA0BBE

P50

Q39858492-32DC4C67-5AEF-4116-B44B-B062254C0D4F

Q39858492-57F5249B-901C-4941-9B30-359EEC39A166

Q39858492-BB19D564-2BE3-48AD-9F37-EF59755BAFCB

Q39858492-E52A3FC5-91C4-4066-865F-568EC5DFE5D7

P577

Q39858492-EC9B3EA8-11A5-4002-94BF-C2DF2FD96615

P5875

Q39858492-271927AC-4515-4029-90E8-A9E67B70CB1D

P698

Q39858492-38780442-F920-4A0D-8A4E-E8567281D34E

P921

Q39858492-149DC580-9697-400D-8F31-3D177556796E

Q39858492-2D3E67F9-7417-4DA5-BECB-36A00C9A9A10

P356

J.JACC.2010.02.046

P1433

Journal of the American College of Cardiology

P1476

Cardiovascular events during differing hypertension therapies in patients with diabetes.

@en

P2093

ACCOMPLISH Investigators

http://www.w3.org/2001/XMLSchema#string

Allen Hester

http://www.w3.org/2001/XMLSchema#string

Eric J Velazquez

http://www.w3.org/2001/XMLSchema#string

George L Bakris

http://www.w3.org/2001/XMLSchema#string

Kenneth Jamerson

http://www.w3.org/2001/XMLSchema#string

Matthew Weir

http://www.w3.org/2001/XMLSchema#string

Michael A Weber

http://www.w3.org/2001/XMLSchema#string

Roxzana Y Kelly

http://www.w3.org/2001/XMLSchema#string

Tsushung A Hua

http://www.w3.org/2001/XMLSchema#string

P304

77-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2010.02.046

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Sverre E. Kjeldsen

Richard B Devereux

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45149806

http://www.w3.org/2001/XMLSchema#string

P698

20620720

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

arterial hypertension